XML 49 R39.htm IDEA: XBRL DOCUMENT v3.22.0.1

Investment in RP Finance, LLC (Details) - USD ($) $ in Thousands	1 Months Ended	3 Months Ended			6 Months Ended
	Aug. 31, 2020	Jan. 31, 2022	Oct. 31, 2021	Jan. 31, 2021	Jan. 31, 2022	Jan. 31, 2021	Sep. 30, 2021	Jul. 31, 2021	Jun. 30, 2021	Nov. 30, 2020	Feb. 03, 2020
Investment in RP Finance, LLC (Details) [Line Items]
Amount of revolving commitment to funds							$ 5,000	$ 10,000	$ 10,000	$ 5,000
Income from interest		$ 0		$ 96
Line of credit facility, description	In August 2020, Rafael Pharmaceuticals called for a $5 million draw on the line of credit facility and the facility was funded by RP Finance LLC in the amount of $5 million, paid in parts in August and September 2020.
Ownership amount					$ 1,875
Cumulative funds description					As of January 31, 2022, the Company has funded a cumulative total of $9.375 million in accordance with its 37.5% ownership interests in RP Finance.
Rafael Pharmaceuticals [Member]
Investment in RP Finance, LLC (Details) [Line Items]
Amount of revolving commitment to funds							$ 5,000			$ 5,000
Percentage of issued and outstanding shares		12.00%			12.00%
Percentage of ownership interest					37.50%
Related party receivable					$ 9,375
RP finance [Member]
Investment in RP Finance, LLC (Details) [Line Items]
Income from interest		$ 575		$ 192
Percentage of ownership interest		37.50%		37.50%	37.50%	37.50%
Equity loss			$ 575
Equity method investment		$ 0			$ 0
Line of Credit Agreement [Member]
Investment in RP Finance, LLC (Details) [Line Items]
Amount of revolving commitment to funds											$ 50,000,000
Description line of credit facility					The Company owns 37.5% of the equity interests in RP Finance and is required to fund 37.5% of funding requests from Rafael Pharmaceuticals under the Line of Credit Agreement. Howard Jonas owns 37.5% of the equity interests in RP Finance, and is required to fund 37.5% of funding requests from Rafael Pharmaceuticals under the Line of Credit Agreement. The remaining 25% equity interests in RP Finance are owned by other shareholders of Rafael Pharmaceuticals.

X

- Definition

Cumulative funds description.

+ References

No definition available.

+ Details

Name:	rfl_CumulativeFundsDescription
Namespace Prefix:	rfl_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- References

No definition available.

+ Details

Name:	rfl_InvestmentinRPFinanceLLCDetailsLineItems
Namespace Prefix:	rfl_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Ownership amount.

+ References

No definition available.

+ Details

Name:	rfl_OwnershipAmount
Namespace Prefix:	rfl_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- Definition

Percentage of issued and outstanding shares of common stock.

+ References

No definition available.

+ Details

Name:	rfl_PercentageOfIssuedAndOutstandingShares
Namespace Prefix:	rfl_
Data Type:	dtr:percentItemType
Balance Type:	na
Period Type:	instant

X

- Definition

Related party receivables.

+ References

No definition available.

+ Details

Name:	rfl_RelatedPartyReceivables
Namespace Prefix:	rfl_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- Definition

Amount of unrealized and realized gain (loss) on investment in debt and equity securities.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(9)(a))
-URI http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(7)(c))
-URI http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227

+ Details

Name:	us-gaap_DebtAndEquitySecuritiesGainLoss
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

This element represents the aggregate cost of investments accounted for under the equity method of accounting.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.12)
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

+ Details

Name:	us-gaap_EquityMethodInvestmentAggregateCost
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

X

- Definition

Description of the terms of a credit facility arrangement. Terms typically include interest rate, collateral required, guarantees required, repayment requirements, and restrictions on use of assets and activities of the entity.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.19(b),22(b))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

+ Details

Name:	us-gaap_LineOfCreditFacilityDescription
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Description of interest rate for borrowing under credit facility. Includes, but is not limited to, terms and method for determining interest rate.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.19(b),22(b))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

+ Details

Name:	us-gaap_LineOfCreditFacilityInterestRateDescription
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

The effective interest rate during the reporting period.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.19(b),22(b))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

+ Details

Name:	us-gaap_LineOfCreditFacilityInterestRateDuringPeriod
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Minimum amount of other commitment not otherwise specified in the taxonomy. Excludes commitments explicitly modeled in the taxonomy, including but not limited to, long-term and short-term purchase commitments, recorded and unrecorded purchase obligations, supply commitments, registration payment arrangements, leases, debt, product warranties, guarantees, environmental remediation obligations, and pensions.

+ References

No definition available.

+ Details

Name:	us-gaap_OtherCommitment
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

X

- Definition

Interest received on loans and other debt instruments during the current period.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 16
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123570139&loc=d3e3337-108585

+ Details

Name:	us-gaap_ProceedsFromInterestReceived
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- Details

Name:	srt_OwnershipAxis=rfl_RafaelPharmaceuticalsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=rfl_RPFinanceMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_ShortTermDebtTypeAxis=us-gaap_LineOfCreditMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type: